טוען...
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in Lewy-bodies, the neuropathologica...
שמור ב:
| הוצא לאור ב: | Front Mol Neurosci |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6906193/ https://ncbi.nlm.nih.gov/pubmed/31866823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnmol.2019.00299 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|